Welcome to a new paradigm in antifungal drug research. Our In Vivo Efficacy Evaluation Services of Antifungal Agents in Non-Mammalian Models offer a cost-effective, high-throughput, and ethically streamlined solution for screening and validating your compounds. By leveraging sophisticated non-mammalian models, we provide critical in vivo data that bridges the gap between in vitro assays and expensive, time-consuming mammalian studies. Our goal is to accelerate your research pipeline, reduce costs, and provide actionable insights into the efficacy of your antifungal candidates. Contact Us for a Customized Quote
Overview of the Service
We offer a comprehensive suite of services for assessing the in vivo efficacy of antifungal agents using established and scientifically validated non-mammalian models. These models, including but not limited to Galleria mellonella (Greater Wax Moth) and Caenorhabditis elegans (Nematode), provide a complete biological system to study host-pathogen interactions, drug bioavailability, and compound toxicity. This service is designed for pharmaceutical companies, biotech startups, and academic researchers seeking to efficiently screen new chemical entities, natural products, or drug repurposing candidates.
Detailed Scope of Services
We offer a modular and customizable service package to meet your specific research needs. Our services can be tailored to investigate:
Workflow
Service Details
Samples
Deliverables
Turnaround Time
Services
-
Prophylactic Efficacy: Administering the compound before infection to prevent fungal growth.
-
Therapeutic Efficacy: Administering the compound after infection to treat the established infection.
-
Minimum Effective Dose (MED) Determination: Establishing the lowest concentration of the drug that demonstrates efficacy.
-
Dose-Response Curve Analysis: Quantifying the relationship between drug concentration and its effect on fungal burden.
-
Time-to-kill Kinetics: Evaluating how quickly the antifungal agent eradicates the fungal pathogen.
-
Drug Combinations: Testing the synergistic or antagonistic effects of multiple compounds.
-
Toxicity and Safety Profiling: Assessing the toxicity of the compound to the host model.
Non-mammalian Model Organisms
-
C. elegans (nematode)
-
Drosophila melanogaster (fruit fly)
-
Danio rerio (zebrafish)
Samples
-
Format: Please provide your compounds in a stable, pre-weighed format.
-
Required Information: Compound name, molecular weight, solubility information, storage conditions, and any relevant safety data sheets (SDS).
-
Quantity: We will specify the required quantity based on the experimental design.
Deliverables
-
Raw Data: All raw data files, including survival curves, CFU counts, and observations.
-
Comprehensive Study Report: A detailed report including the study design, methodology, results (presented in tables and graphs), statistical analysis, and a professional summary of the findings.
-
Presentation of Results: A virtual meeting with our scientific team to review the data and discuss next steps.
Turnaround Time
Our efficient, high-throughput models allow for significantly faster turnaround times compared to traditional mammalian studies. A standard efficacy screen can be completed within 5-7 weeks from the receipt of your compounds, depending on the complexity of the study design.
Ready to discuss your project? Let us get in touch and explore how our consulting services can help you achieve your goals.
Mechanism of Action & Scientific Basis
Non-mammalian models like Galleria mellonella possess a functional innate immune system with striking similarities to that of mammals, including hemocytes that phagocytose pathogens, and a humoral response that secretes antimicrobial peptides. This makes it an ideal model for studying the effects of antifungal agents on pathogen survival and dissemination within a living host. The transparent nature of C. elegans allows for real-time visualization of fungal infection and the impact of the drug, providing unique insights into the mechanism of action.
Our Advantages
Cost-Effectiveness
Substantially lower costs than mammalian efficacy studies.
High-Throughput Screening
Our models are scalable for testing a large number of compounds simultaneously.
Ethically Compliant
Reduces the need for vertebrate animals in early-stage drug development, aligning with the 3Rs principles (Replace, Reduce, Refine).
Physiologically Relevant
Provides genuine in vivo data that accounts for complex host-pathogen interactions and drug metabolism.
Reproducible & Robust
Our standardized protocols ensure consistent and reliable results.
Rapid Turnaround
Accelerate your decision-making and project timelines.
Applications
-
Primary Efficacy Screening: Identifying lead candidates from a large library of compounds.
-
Lead Optimization: Fine-tuning the structure-activity relationship (SAR) of promising candidates.
-
Drug Repurposing: Screening existing drugs for new antifungal indications.
-
Combination Therapy Studies: Evaluating synergistic effects of different antifungal agents.
-
Natural Product Research: Assessing the antifungal potential of extracts or isolated compounds.
Contact us today to schedule a free consultation and discover how our In Vivo Efficacy Evaluation Services can help you bring the next generation of antifungal treatments to market faster.
Your next breakthrough is just a conversation away. Let's talk about your challenges and find a custom solution together.
FAQs
Which non-mammalian model is right for my project?
We will consult with you to select the best model based on the fungal pathogen, compound type, and specific research questions.
Can you test novel fungal strains?
Yes, we have a BSL-2 lab and can work with most fungal pathogens. Please contact us to discuss the specifics.
How do you handle compound solubility issues?
Our team has extensive experience in formulating compounds for in vivo administration. We will work with you to find a suitable vehicle.
